Volume 3.23 | Jun 12

LABORATORY RESEARCH

Autocrine Activation of the MET Receptor Tyrosine Kinase in Acute Myeloid Leukemia
These results show a widespread dependence of acute myeloid leukemia cells on autocrine activation of MET, as well as the key role of compensatory upregulation of hepatocyte growth factor expression in maintaining leukemogenic signaling by this receptor. [Nat Med] Abstract

Dual Actions of Meis1 Inhibit Erythroid Progenitor Development and Sustain General Hematopoietic Cell Proliferation 
Researchers showed that myeloid ecotropic viral integration site 1 (Meis1) exerts two independent functions, with its role in proliferation of hematopoietic progenitors acting earlier in development and its influence on the fate choice at the megakaryocyte-erythroid progenitor stage between megakaryocytic and erythroid development. [Blood] Abstract

Mouse Hematopoietic Cell-Targeted STAT3 Deletion: Stem/Progenitor Cell Defects, Mitochondrial Dysfunction, ROS Overproduction, and a Rapid Aging-Like Phenotype
Scientists studied hematopoietic cell-targeted deletion of the STAT3 gene in hematopoietic stem/progenitor cells with a focus on mitochondrial function. [Blood] Abstract

Expression of MALT1 Oncogene in Hematopoietic Stem/Progenitor Cells Recapitulates the Pathogenesis of Human Lymphoma in Mice
Investigators showed that human-like lymphomas can be modeled in mice by targeting mucosa-associated lymphoid tissue (MALT) expression to hematopoietic stem/progenitor cells, demonstrating the oncogenic role of MALT1 in lymphomagenesis. [Proc Natl Acad Sci USA] Abstract | Full Article

5-Androstene-3β,17β-Diol Promotes Recovery of Immature Hematopoietic Cells following Myelosuppressive Radiation and Synergizes with Thrombopoietin
5-Androstene-3β,17β-diol (5-AED) stimulates recovery of hematopoiesis after exposure to radiation. To elucidate its cellular targets, the effects of 5-AED alone and in combination with granulocyte colony-stimulating factor and thrombopoietin on immature hematopoietic progenitor cells were evaluated following total body irradiation. [Int J Radiat Oncol Biol Phys] Abstract

The Cytosolic Protein G0S2 Maintains Quiescence in Hematopoietic Stem Cells
Scientists propose a novel model of hematopoietic stem cell quiescence in which elevated G₀/G₁ switch gene 2 (G0S2) expression can sequester nucleolin in the cytosol, precluding its pro-proliferation functions in the nucleolus. [PLoS One] Full Article | Press Release

LSK Derived LSK^– Cells Have a High Apoptotic Rate Related to Survival Regulation of Hematopoietic and Leukemic Stem Cells
These results indicate a potential function of the Lin^–Sca-1⁺c-Kit^– (LSK^–) cells in the regulation of Lin^–Sca-1⁺c-Kit⁺ (LSK) cells and leukemia stem cells. [PLoS One] Full Article

JAK-STAT and AKT Pathway-Coupled Genes in Erythroid Progenitor Cells through Ontogeny
Researchers aimed to observe the function of erythropoietin (EPO) activation of JAK-STAT and phosphatidylinositol 3-kinase/AKT pathways in the development of erythroid progenitors from hematopoietic CD34+ progenitor cells, as well as to distinguish early EPO target genes in human erythroid progenitors during ontogeny. [J Transl Med] Abstract | Full Article

CLINICAL RESEARCH

Radiation Exposure from CT Scans in Childhood and Subsequent Risk of Leukemia and Brain Tumors: A Retrospective Cohort Study
Scientists aimed to assess the excess risk of leukemia and brain tumors after CT scans in a cohort of children and young adults. [Lancet] Abstract | Press Release

Administration of Imatinib after Allogeneic Hematopoietic Stem Cell Transplantation May Improve Disease-Free Survival for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Researchers investigated the safety of imatinib and its efficacy in preventing hematological relapse and improving disease free survival when administered after allogeneic hematopoietic stem cell transplantation. [J Hematol Oncol] Abstract | Full Article

ARIAD Announces Updated Data from Pivotal PACE Trial of Ponatinib, Its Investigational Pan-BCR-ABL Inhibitor
ARIAD Pharmaceuticals, Inc. announced updated clinical data from the pivotal PACE trial of ponatinib in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia, who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation. [Press release from ARIAD Pharmaceuticals, Inc. discussing research presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, Chicago] Press Release

Omacetaxine Mepesuccinate Shows Activity in Chronic Myeloid Leukemia Patients Who Have Become Resistant to or Intolerant of Prior Tyrose Kinase Inhibitors
Teva Oncology presented two secondary analyses featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor. [Press Release from Teva Pharmaceuticals discussing research presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, Chicago] Press Release

Preeminent Tissue Engineering Team to Establish Program at Nationwide Children’s Hospital
Breuer and Shinoka were the first in the world to tissue engineer blood vessels and implant them in human infants for repair of congenital heart defects. They currently have US Food and Drug Administration approval to conduct the first U.S human trial to investigate the safety and effectiveness of this method. They and their team will conduct this work at Nationwide Children’s Hospital. [Nationwide Children’s Hospital] Press Release

TeSR™-E8™ and STEMdiff™: New Products to Advance Research on Human Pluripotent Stem Cells
STEMCELL Technologies Inc. announced its plans to release a series of new products to advance research and translational applications for human pluripotent stem cells. [STEMCELL Technologies Inc.]
Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW World Cord Blood Congress
September 20-21, 2012
Boston, United States
  
Visit our events page to see a complete list of events in the hematopoietic community.

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Postdoctoral Fellowship – Cellular Origin of Blood Cells (European Molecular Biology Laboratory)

PhD Position – Construction of a Biomimetic, Hematopoietic Stem Cell Niche (Karlsruhe Institute of Technology – Helmholtz Association)

Postdoctoral Position – Hematopoietic Stem Cell Biology and Immunology (University of California, San Francisco)

Postdoctoral Position – Hematopoietic Lineage Commitment and Leukemia Development (University of Oxford – Weatherall Institute of Molecular Medicine)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!